MarketCap
Facebook
X
Telegram
Titan Pharmaceuticals Balance Sheet 2024-2008 | TTNP
Brief overview of Titan Pharmaceuticals's balance sheet strength
The comparison uses five available annual reports from the 2020–2024 interval.
The asset base decreased -63.9%, from $8.1 million to $2.9 million. Resources became smaller over the five periods.
Liability growth of -89.4% trailed asset growth of -63.9%. The funding structure became more resilient.
The equity ratio reached 83.5% from 43.7%. A high capital share reduces dependence on liabilities.
The cash share moved from 66.9% to 96.9%. A higher figure generally provides more room in an adverse scenario.
Retained earnings remain negative at -$396.5 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
What the balance sheet shows
Titan Pharmaceuticals's balance sheet sends more positive than negative signals, but liabilities should not begin outpacing the capital base.
Annual Balance Sheet Titan Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | -2.75 M | -5.74 M | -4.94 M | -782 K | -4.98 M | -938 K | -14 M | -7.86 M | -15.5 M | -11.8 M | -6.24 M | 6.85 M | 4.09 M | - | - |
Long Term Debt |
- | - | 65 K | 187 K | 327 K | 4.02 M | 3.79 M | 3.58 M | - | - | - | - | 9.36 M | 12.3 M | 5.4 M | - | - |
Long Term Debt Current |
- | 65 K | 122 K | 112 K | 150 K | 272 K | 527 K | 3 M | - | - | - | - | 2.5 M | - | 1.87 M | - | - |
Total Non Current Liabilities |
- | - | - | - | 327 K | 4.49 M | 3.81 M | 3.58 M | 619 K | 1.44 M | 5.58 M | 1.82 M | 26.6 M | 25.2 M | - | - | - |
Total Current Liabilities |
483 K | 1.44 M | 2.63 M | 2.67 M | 4.22 M | 3.6 M | 3.45 M | 4.46 M | 4.86 M | 4.85 M | 6.66 M | 10.8 M | 21.4 M | 5.12 M | 5.4 M | - | - |
Total Liabilities |
483 K | 1.44 M | 2.7 M | 2.86 M | 4.56 M | 8.09 M | 7.26 M | 8.05 M | 5.48 M | 6.3 M | 12.2 M | 12.7 M | 48 M | 30.3 M | 10.8 M | - | - |
Deferred Revenue |
- | - | - | - | - | - | 313 K | - | - | - | 1.67 M | 5.32 M | 14.4 M | - | - | - | - |
Retained Earnings |
-397 M | -392 M | -386 M | -376 M | - | -349 M | -333 M | -323 M | -309 M | -314 M | -303 M | -300 M | -310 M | -295 M | -280 M | - | - |
Total Assets |
2.92 M | 8.09 M | 4.06 M | 7.99 M | 8.09 M | 9.52 M | 14.1 M | 8.9 M | 18.7 M | 13.3 M | 20.9 M | 18.4 M | 24.8 M | 10.2 M | 4.75 M | - | - |
Cash and Cash Equivalents |
2.83 M | 6.76 M | 2.94 M | 6.04 M | 5.41 M | 5.22 M | 9.3 M | 7.52 M | 14 M | 7.86 M | 15.5 M | 11.8 M | 18.1 M | 5.41 M | 3.18 M | 3.3 M | 4.67 M |
Book Value |
2.44 M | 6.64 M | 1.36 M | 5.14 M | 3.53 M | 1.43 M | 6.83 M | 857 K | 13.2 M | 6.99 M | 8.61 M | 5.76 M | -23.1 M | -20.1 M | -6.05 M | - | - |
Total Shareholders Equity |
2.44 M | 6.64 M | 1.36 M | 5.14 M | 3.53 M | 1.43 M | 6.83 M | 857 K | 13.2 M | 6.99 M | 8.61 M | 5.76 M | -23.1 M | -20.1 M | -6.05 M | -1.45 M | 1.79 M |
All numbers in USD currency
Quarterly Balance Sheet Titan Pharmaceuticals
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | - | - | 33 K | 65 K | 96 K | 128 K | 158 K | 187 K | - | - | 88 K | 332 K | 332 K | 332 K | 332 K | 4.02 M | 4.02 M | 4.02 M | 4.02 M | 3.79 M | 3.79 M | 3.79 M | 3.79 M | 3.58 M | 3.58 M | 3.58 M | 3.58 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.36 M | 9.36 M | 9.36 M | 9.36 M | 12.3 M | 12.3 M | 12.3 M | 12.3 M |
Total Liabilities |
263 K | 279 K | 483 K | 371 K | 356 K | 559 K | 1.44 M | 1.87 M | 1.85 M | 2.48 M | 2.7 M | 2.73 M | 2.65 M | 2.44 M | 2.86 M | 2.14 M | 2.76 M | 3.84 M | 4.56 M | 4.56 M | 4.56 M | 4.56 M | 8.09 M | 8.09 M | 8.09 M | 8.09 M | 7.26 M | 7.26 M | 7.26 M | 7.26 M | 8.05 M | 8.05 M | 8.05 M | 8.05 M | 5.48 M | 5.48 M | 5.48 M | 5.48 M | 6.3 M | 6.3 M | 6.3 M | 6.3 M | 12.2 M | 12.2 M | 12.2 M | 12.2 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 48 M | 48 M | 48 M | 48 M | 30.3 M | 30.3 M | 30.3 M | 30.3 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 313 K | 626 K | 939 K | 313 K | - | - | - | - | - | - | - | - | - | - | - | 760 K | 1.67 M | 1.67 M | 1.67 M | 1.67 M | 5.32 M | 5.32 M | 5.32 M | 5.32 M | 14.4 M | 14.4 M | 14.4 M | 14.4 M | - | - | - | - |
Retained Earnings |
-398 M | -397 M | -397 M | -396 M | -395 M | -393 M | -392 M | -390 M | -390 M | -388 M | -386 M | -384 M | -381 M | -379 M | -376 M | -374 M | -372 M | -370 M | -367 M | -367 M | -367 M | -367 M | -349 M | -349 M | -349 M | -349 M | -333 M | -333 M | -333 M | -333 M | -323 M | -323 M | -323 M | -323 M | -309 M | -309 M | -309 M | -309 M | -314 M | -314 M | -314 M | -314 M | -303 M | -303 M | -303 M | -303 M | -300 M | -300 M | -300 M | -300 M | -310 M | -310 M | -310 M | -310 M | -295 M | -295 M | -295 M | -295 M |
Total Assets |
3.05 M | 2.16 M | 2.92 M | 3.6 M | 4.35 M | 6.65 M | 8.09 M | 10 M | 812 K | 2.17 M | 4.06 M | 6.28 M | 8.32 M | 10.3 M | 7.99 M | 9.64 M | 11.5 M | 13.8 M | 8.09 M | 8.09 M | 8.09 M | 8.09 M | 9.52 M | 9.52 M | 9.52 M | 9.52 M | 14.1 M | 14.1 M | 14.1 M | 14.1 M | 8.9 M | 8.9 M | 8.9 M | 8.9 M | 18.7 M | 18.7 M | 18.7 M | 18.7 M | 13.3 M | 13.3 M | 13.3 M | 13.3 M | 20.9 M | 20.9 M | 20.9 M | 20.9 M | 18.4 M | 18.4 M | 18.4 M | 18.4 M | 24.8 M | 24.8 M | 24.8 M | 24.8 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M |
Cash and Cash Equivalents |
2.8 M | 1.94 M | 2.83 M | 3.4 M | 4.09 M | 6.16 M | 6.76 M | 8.1 M | 105 K | 1.14 M | 2.94 M | 4.45 M | 6.42 M | 8.14 M | 6.04 M | 7.42 M | 9.68 M | 11.6 M | 5.41 M | 5.41 M | 5.41 M | 5.41 M | 5.22 M | 5.22 M | 5.22 M | 5.22 M | 9.3 M | 9.3 M | 9.3 M | 9.3 M | 7.52 M | 7.52 M | 7.52 M | 7.52 M | 14 M | 14 M | 14 M | 14 M | 7.86 M | 7.86 M | 7.86 M | 7.86 M | 15.5 M | 15.5 M | 15.5 M | 15.5 M | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 18.1 M | 18.1 M | 18.1 M | 18.1 M | 5.41 M | 5.41 M | 5.41 M | 5.41 M |
Book Value |
2.79 M | 1.88 M | 2.44 M | 3.23 M | 3.99 M | 6.09 M | 6.64 M | 8.13 M | -1.03 M | -312 K | 1.36 M | 3.55 M | 5.67 M | 7.88 M | 5.14 M | 7.5 M | 8.75 M | 9.98 M | 3.53 M | 3.53 M | 3.53 M | 3.53 M | 1.43 M | 1.43 M | 1.43 M | 1.43 M | 6.83 M | 6.83 M | 6.83 M | 6.83 M | 857 K | 857 K | 857 K | 857 K | 13.2 M | 13.2 M | 13.2 M | 13.2 M | 6.99 M | 6.99 M | 6.99 M | 6.99 M | 8.61 M | 8.61 M | 8.61 M | 8.61 M | 5.76 M | 5.76 M | 5.76 M | 5.76 M | -23.1 M | -23.1 M | -23.1 M | -23.1 M | -20.1 M | -20.1 M | -20.1 M | -20.1 M |
Total Shareholders Equity |
2.79 M | 1.88 M | 2.44 M | 3.23 M | 3.99 M | 6.09 M | 6.64 M | 8.13 M | -1.03 M | -312 K | 1.36 M | 3.55 M | 5.67 M | 7.88 M | 5.14 M | 7.5 M | 8.75 M | 9.98 M | 3.53 M | 3.53 M | 3.53 M | 3.53 M | 1.43 M | 1.43 M | 1.43 M | 1.43 M | 6.83 M | 6.83 M | 6.83 M | 6.83 M | 857 K | 857 K | 857 K | 857 K | 13.2 M | 13.2 M | 13.2 M | 13.2 M | 6.99 M | 6.99 M | 6.99 M | 6.99 M | 8.61 M | 8.61 M | 8.61 M | 8.61 M | 5.76 M | 5.76 M | 5.76 M | 5.76 M | -23.1 M | -23.1 M | -23.1 M | -23.1 M | -20.1 M | -20.1 M | -20.1 M | -20.1 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Titan Pharmaceuticals, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
China
Israel
France
Germany
Britain
Russia
Belgium
Cayman-islands
